Gavin McLeod, MD
Infectious Disease · Stamford, CTNPI 1386616662
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $6,420 of the $8,712 with a category attached, or 73.7%. Gilead accounts for 97.9% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $8,607 and has fallen 99.6% since, to $36 in 2024. Among infectious disease clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 28 payments — averaging $311.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$9K
- Johnson & Johnson$83
- Janssen Products, LP$50
- Merck$28
- Viiv Healthcare Company$14
- Vyera Pharmaceuticals, LLC$12
Across 2 payments — averaging $5616.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$11K
What the payments were for
- Speaking & faculty fees$6,42074%
- Travel & lodging$1,78621%
- Food & beverage$4555%
- Education$501%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 18 | $8,525 |
| Johnson & Johnson | 5 | $83 |
| Janssen Products, LP | 1 | $50 |
| Merck | 2 | $28 |
| Viiv Healthcare Company | 1 | $14 |
| Vyera Pharmaceuticals, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Biktarvy$1,040
How this compares
$8,712 in reported general payments places this provider in the 90th percentile of 159 infectious disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 198 | $913,526 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 24 | $92,082 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 13 | $52,024 |
| PifeltroDoravirine | 20 | $44,168 |
| DovatoDolutegravir Sodium/Lamivudine | 14 | $38,378 |
| DescovyEmtricitabine/Tenofov Alafenam | 12 | $26,002 |
| Darunavir | 13 | $20,523 |
| EliquisApixaban | 13 | $6,834 |
| Atovaquone-Proguanil HclAtovaquone/Proguanil Hcl | 13 | $1,022 |
| Doxycycline Hyclate | 32 | $1,010 |
| Ethambutol Hcl | 11 | $798 |
| Azithromycin | 15 | $623 |
| Penicillin V Potassium | 23 | $451 |
| Rifampin | 14 | $342 |
| Cephalexin | 13 | $257 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $8,525 | $991,553223 claims |
| MerckPifeltro | $28 | $44,16820 claims |
| Viiv Healthcare CompanyDovato | $14 | $38,37814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 159 infectious disease providers in Connecticut.
Other infectious disease in Stamford
- Zane SaulStratford$513K
- Stephen ScholandMeriden$428K
- Onyema OgbuaguNew Haven$412K
- David RubinNorwalk$397K
- Steven SchnittmanWest Haven$363K
- Kalpana GuptaWest Haven$160K
- Frederick AlticeNew Haven$143K
- Paul AnthonyHartford$91K
- Adrian DemidontHamden$90K
- Albert KoNew Haven$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.